COVID-19 Preparedness and Response Plan


In accordance with Executive Order 2020-59, Yonick Plastic Surgery and Aesthetic Center (“Company”) institutes this COVID-19 Preparedness and Response Plan (“Plan”).

Company aims to protect its patients and workforce by enacting all appropriate prevention efforts. Company is continually monitoring guidance from local, state, and federal health officials and implementing workplace and Plan modifications where appropriate.


Prevention Efforts and Office Controls


Cleanliness and Social Distancing

Company abides by the recommended social distancing and other safety measures and establishes the following:

  • Large gatherings > 10 persons are minimized whenever possible;
  • Patients are encouraged to maintain physical distance while in the office;
  • Patients will remain no fewer than six feet apart; and
  • Patient interactions with employees of the Company are modified, when able, to allow for additional physical space between parties.

Company provides patients with appropriate grade face coverings, which are to be worn at all times.

In addition, Company is instituting the following cleanliness measures:

  • When working on site main floor or in proximity to any patients, employees will be required to wear an appropriate face covering that will be assigned to them;
  • Where possible, increasing ventilation rates and circulation throughout office building;
  • Performing routine environmental cleaning and disinfection, especially of common areas; and
  • Where available, providing hand sanitizer in high-traffic areas.

Both patients and employees of Company are expected to minimize COVID-19 exposure by:

  • Washing hands with soap and water for at least 20 seconds;
  • Utilizing hand sanitizer when soap and water are unavailable;
  • Avoiding touching their faces with unwashed hands;
  • Avoiding handshakes or other physical contact;
  • Practicing respiratory etiquette, including covering coughs and sneezes;
  • Immediately reporting unsafe or unsanitary conditions on Company premises;
  • Complying with Company’s screening processes;
  • Seeking medical attention and/or following medical advice if experiencing COVID-19 symptoms; and
  • Complying with self-isolation or quarantine orders.

Identification and Isolation of Sick and/or Exposed Patients


Patient Self-Monitoring

The following patients should not visit the Office and, upon notification to Company, will be asked to leave and return when well:

  • Patients who display COVID-19 symptoms, such as fever, cough, shortness of breath, sore throat, new loss of smell or taste, and/or gastrointestinal problems, including nausea, diarrhea, and vomiting, whether or not accompanied by a formal COVID-19 diagnosis;
  • Patients who, in the last 14 days, have had close contact with and/or live with any person having a confirmed COVID-19 diagnosis; and
  • Patients who, in the last 14 days, have had close contact with and/or live with any person displaying COVID-19 symptoms, such as fever, cough, shortness of breath, sore throat, new loss of smell or taste, and/or gastrointestinal problems, including nausea, diarrhea, and vomiting.

Daily Screenings

Patients are asked the following questions before entering the Office:

  • Are you currently suffering from any of the following symptoms – fever, cough, shortness of breath, sore throat, new loss of smell or taste, and/or gastrointestinal problems, including nausea, diarrhea, and vomiting?
    • A touchless thermometer is available, and temperature checks will be performed.
    • If yes, access is denied, and patient is advised to self-isolate/self-quarantine at home, until patient is permitted to return as defined below.
  • Have you lived with, or had close contact with, someone in the last 14 days diagnosed with or displaying the symptoms of COVID-19?
    • If yes, access is denied, and patient is advised to self-isolate/self-quarantine at home, until at least 14 days after the close contact.
  • Have you travelled via airplane internationally or domestically in the last 14 days?
    • If yes, access is denied, and patient is advised to self-isolate/self-quarantine at home, until at least 14 days after the international or domestic travel.

Patients who develop symptoms during their visit must immediately report to any staff member of the Company.


Return-to-Office Requirements

Patients who were themselves diagnosed with COVID-19 may only enter the Office upon confirmation of the cessation of symptoms and contagiousness, proof of which may be acquired via the test-based strategy or the non-test-based strategy.

The test-based strategy is preferred but relies upon the availability of testing supplies and laboratory capacity. Under this strategy, patients may discontinue isolation and return to work upon achieving the following conditions:

  • Resolution of fever without the use of fever-reducing medications;
  • Improvement in respiratory symptoms (e.g., cough, shortness of breath); and
  • Negative results of an FDA Emergency Use Authorized molecular assay for COVID-19 from two consecutive nasopharyngeal swab specimens collected at least 24 hours apart.

Under the non-test-based strategy, patients may discontinue isolation and return to the Office upon achieving the following conditions:

  • At least 3 days (72 hours) have passed since recovery defined as resolution of fever without the use of fever-reducing medications;
  • Improvement in respiratory symptoms (e.g., cough, shortness of breath); and
  • At least 7 days have passed since symptoms first appeared.

Patients who came into close contact with, or live with, an individual with a confirmed diagnosis or symptoms may return to the Office after either 14 days have passed since the last close contact with the diagnosed/symptomatic individual, or the diagnosed/symptomatic individual receives a negative COVID-19 test.